Riverview Trust Company’s Ionis Pharmaceuticals IONS Stock Holding History

Riverview Trust Company’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-476	Closed	-$14.4K	–	392
2025 Q1	$14.4K	Hold	476	–	–	0.01%	540
2024 Q4	$16.6K	Sell	476 -11	-2%	-$411	0.02%	533
2024 Q3	$19.5K	Buy	487 +11	+2%	+$512	0.02%	492
2024 Q2	$22.7K	Hold	476	–	–	0.02%	385
2024 Q1	$20.6K	Buy	+476	New	+$22.7K	0.02%	463
2023 Q4	–	Sell	-476	Closed	-$21.6K	–	354
2023 Q3	$21.6K	Hold	476	–	–	0.02%	364
2023 Q2	$19.5K	Hold	476	–	–	0.02%	373
2023 Q1	$17K	Hold	476	–	–	0.02%	410
2022 Q4	$18K	Hold	476	–	–	0.02%	355
2022 Q3	$21K	Hold	476	–	–	0.02%	355
2022 Q2	$18K	Hold	476	–	–	0.02%	422
2022 Q1	$18K	Buy	+476	New	+$15.6K	0.01%	530

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Riverview Trust Company's IONS Position: Q2 2025 in Review

Riverview Trust Company sold out of Ionis Pharmaceuticals (IONS) in Q2 2025, closing a stake of 476 shares — an estimated $14.4K sold.

Riverview Trust Company first reported a position in IONS in Q1 2022 and held it in 12 quarters. The position peaked at $22.7K in Q2 2024. 362 funds tracked by Wall St. Rank hold IONS as of Q2 2025.

Riverview Trust Company reported no remaining Ionis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Riverview Trust Company sold 476 Ionis Pharmaceuticals shares in Q2 2025, an estimated $14.4K.
Riverview Trust Company first reported a position in Ionis Pharmaceuticals in Q1 2022 and held it in 12 quarters.
Riverview Trust Company's Ionis Pharmaceuticals position peaked at $22.7K in Q2 2024.
362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2025.

Based on Riverview Trust Company's 13F filing for Q2 2025, filed 21 Jul 2025.